Regulatory perspectives on HEOR
Presenter and moderator disclosures:
The following panelists and moderator have no financial relationships to disclose:
Fraser Bocell, MEd, PhD; Mitchell Levine, MD, MSc, FRCPC, FACP, FISPE; Sarah Norris, PhD; Tieuvi Nguyen, PhD; Kevin D. Frick, PhD (Moderator)
The following panelist disclosed financial relationships:
Christopher McCabe, PhD: Astra Zeneca: (F); Boeringher Ingleheim: (F); GlaxosmithKline: (F); Roche: (F); Takeda: (F); Merck: (F); Novartis: (F)
Fraser Bocell, MEd, PhD; Mitchell Levine, MD, MSc, FRCPC, FACP, FISPE; Sarah Norris, PhD; Tieuvi Nguyen, PhD; Kevin D. Frick, PhD (Moderator)
The following panelist disclosed financial relationships:
Christopher McCabe, PhD: Astra Zeneca: (F); Boeringher Ingleheim: (F); GlaxosmithKline: (F); Roche: (F); Takeda: (F); Merck: (F); Novartis: (F)
Description
Exploring HEOR questions can be more impactful when the answers provide data that matter to government agencies and regulators. Representatives from the U.S. FDA, Ophthalmic Devices Division, the Patented Medicine Prices Review Board of Canada, and the Pharmaceutical Benefits Scheme (PBS) of Australia will talk about the data examined by their agencies.This session ends with a synthesis of the day’s topics and a preview of Day 3.